Thu, March 3, 2022
Wed, March 2, 2022
Tue, March 1, 2022
Mon, February 28, 2022
Sun, February 27, 2022
Fri, February 25, 2022

Tazeen Ahmad Maintained (ACAD) at Hold with Decreased Target to $31 on, Mar 1st, 2022


  Copy link into your clipboard //stocks-investing.news-articles.net/content/202 .. with-decreased-target-to-31-on-mar-1st-2022.html
  Print publication without navigation Published in Stocks and Investing on by WOPRAI
          🞛 This publication is a summary or evaluation of another publication

Tazeen Ahmad of B of A Securities, Maintained "ACADIA Pharmaceuticals Inc." (ACAD) at Hold with Decreased Target from $32 to $31 on, Mar 1st, 2022.

Tazeen has made no other calls on ACAD in the last 4 months.



There are 9 other peers that have a rating on ACAD. Out of the 9 peers that are also analyzing ACAD, 6 agree with Tazeen's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Increased Target to $30 on, Wednesday, December 22nd, 2021
  • Yatin Suneja of "Guggenheim" Downgraded from Strong Buy to Hold and Held Target at $28 on, Tuesday, December 21st, 2021
  • Jay Olson of "Oppenheimer" Maintained at Hold with Increased Target to $23 on, Thursday, December 9th, 2021
  • Salveen Richter of "Goldman Sachs" Maintained at Hold with Increased Target to $28 on, Wednesday, December 8th, 2021
  • Vamil Divan of "Mizuho" Maintained at Hold with Increased Target to $26 on, Tuesday, December 7th, 2021
  • Jeffrey Hung of "Morgan Stanley" Maintained at Hold with Increased Target to $24 on, Tuesday, December 7th, 2021


These are the ratings of the 3 analyists that currently disagree with Tazeen


  • Andrew Fein of "HC Wainwright & Co." Upgraded from Hold to Strong Buy and Increased Target to $36 on, Wednesday, February 9th, 2022
  • Neena Bitritto-Garg of "Citigroup" Upgraded from Hold to Strong Buy and Held Target at $30 on, Wednesday, January 5th, 2022
  • Gregory Renza of "RBC Capital" Maintained at Buy with Increased Target to $34 on, Tuesday, December 21st, 2021

Publication Contributing Sources